Targeting dendritic cells (DCs) for immunotherapy represents a powerful approach for harnessing the patient's own immune system to eliminate cancer cells or to limit chronic infection. Immunostimulatory DCs as vaccine adjuvants have been applied and tested in both conditions, with some encouraging results. However, immune suppression mediated by tumors and the tumor microenvironment or chronic viral infection, limits the potential of DC based vaccines and compromises DC activity and that of other innate immune cells in the TME. Targeting DC in situ represents another approach to boost immunity in vivo. Along these lines, DC targeted approaches include antibodies that bind DC receptors and agonists or alarmins that prime DC via multiple pattern recognition receptors. The presentation will address the activities of some of these various agents and the imprinting of adjuvant activity upon DC in vitro and in clinical trials. Combining DC targeted vaccines with new approaches that enhance immunogenicity and overcome the regulatory mechanisms underlying peripheral tolerance may be the key to achieving effective and durable immune responses that translate to better clinical outcomes.
Citation Format: Nina Bhardwaj. Vaccines targeting innate immune cells. [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2015;3(10 Suppl):Abstract nr IA24.
- ©2015 American Association for Cancer Research.